Development

>

Latest News

Science laboratory test tubes, laboratory equipment | Image Credit: © BillionPhotos.com - © BillionPhotos.com - stock.adobe.com
Roche Announces Prasinezumab Missed Primary Endpoint in Phase IIb Study, but Shows Possible Benefit in Treating Early Stage Parkinson’s Disease

December 24th 2024

The results garnered from the Phase IIb study failed to achieve statistical significance in the primary endpoint.

Science laboratory test tubes, laboratory equipment | Image Credit: © BillionPhotos.com - © BillionPhotos.com - stock.adobe.com
Orexo Collaborates with Abera on Nasal Powder Vaccines

December 19th 2024

Colorful 3D glass molecules and atoms in blue background. | Image Credit: ©Drawbot - stock.adobe.com
MHC-Associated Peptide Proteomics: Immunogenicity and Vaccine Design

December 18th 2024

Science laboratory test tubes, laboratory equipment | Image Credit: © BillionPhotos.com - © BillionPhotos.com - stock.adobe.com
AbbVie to Acquire Nimble Therapeutics, Further Strengthening Immunology Pipeline

December 17th 2024

Science laboratory test tubes, laboratory equipment | Image Credit: © BillionPhotos.com - © BillionPhotos.com - stock.adobe.com
AbbVie Completes $1.4 Billion Acquisition of Aliada Therapeutics, Boosting Neuroscience Pipeline

December 17th 2024

Research into Cold Cancers Heating Up

Accurately targeted immunotherapies through reliable neoantigen recognition enable personalized medicine development.

Research into Cold Cancers Heating Up; Image: catalin - stock.adobe.com

More News

Large-Scale Manufacturing of Plasmid DNA for Gene Therapy and DNA Vaccination -- Part 1: The Suitability of Current Techniques to Purify Plasmid Without Adding RNase

Large-Scale Manufacturing of Plasmid DNA for Gene Therapy and DNA Vaccination -- Part 1: The Suitability of Current Techniques to Purify Plasmid Without Adding RNase

Alex Eon-Duval
August 1st 2003

Although gene therapy and DNA vaccination suggest promising new approaches to disease treatment - and nonviral vectors (which are cheap and easy to manufacture) afford low immunogenicity, better safety profiles, and improved stability - commercial-scale purification of plasmid DNA remains difficult, particularly if bovine-derived ribonuclease A is left out of the process. This article series reviews the benefits and limitations of current plasmid DNA purification and suggests an RNase-free downstream process that is scalable, robust, and meets the requirements set by industry regulators.

<1
...
5152535455
© 2024 MJH Life Sciences

All rights reserved.